Member Info for Spuddymadrid

I am a private shareholder. I expressed my opinion. You may be correct or I maybe correct. I want the share price to rise as I am a holder. I could sell my shares now but prefer to hold. You believe the share price will drop so I imagine you have sold all your shares. If not why not ?. It is slow going I agree. Basically I am positive on the company

And you are negative. Equally valid opinions. Regards

No doubt you have already sold all your shares Marc. So why bother commenting. A deal will be completed soon !!. Bad move on your part. JMO

My thinking on this is that a deal of some sort on Polb-001 or one of our other drugs is close. Poolbeg stated on x today that they are well positioned to generate shareholder value. Cannot see any dilution in the short term at present levels on the back of this statement. Perhaps following a deal and at a higher share price more shares will be issued

Moniman - Cash you could both be right. Something going on. Could be a partnership deal for Polb-0001 mixed with an RTO leading to a Nasdaq listing. Hope you are both well !!

Here are some snippets

The company is clearly getting ready for a slate of deals, with the ultimate goal of backing into a listing on New York’s Nasdaq stock exchange.

We are looking at Nasdaq companies that maybe are faltering,” he says. “They might have interesting pipelines or products, maybe they need additional capital.”

It’s a well-worn path and we’ve got people in place who have done it,” he says. “The company is going to reverse in and it’s going to drive value in the pipeline.

But a key step on the road to developing these promising treatments fully will be the access to capital and the shop window afforded by the Nasdaq. And the plan is to get it done in the next year or so.

Nasdaq is the place to be,” Skillington says. “A lot of work has been done since [the IPO]. It was a good starting point. We’ve done well enough. We’d like to be pushing forward.”

Thank you very much my Friend. Will have a look. Take care

Hello Bazzaman. How are things ? Do you have a link to the podcast. Regards

Hello Swizz/Makeabundle. Have a question. If the Barryroe license does or does not get reinstated and landsdowne RTOs does the resultant entity have the right to recover previous operating and our capital losses. I imagine the jurisdiction is the UK for tax purposes. Logp must have big operating and tax losses racked up down through the years.

Meant to say in trouble in terms of !!!

Morning Id10t. The strange thing is it is more likely a deal is near when they give the inpression of being less excited. They cannot announce their belief a deal is near. If any potential deal fell through they would be in terms of misleading the market through false information. So I will hold tight and try to be patient

Hello Farris. There is no link. Perhaps the presentation will be posted by Poolbeg in the coming days. Regards Spuddy

Helli there id10t. I was also on the call and unfortunately did not get my questions aired due to lack of time. Very little released vis-a-vis Polb-001. Whilst I agree that they were quite vague in their responses, some responses point toward considerable activity. 1: Mention of possible merger with Biotech on Nasdaq where Poolbeg and its products being an EMEA based company would be a great fit. 2: The two major nasdaq listed pharmas have signed off on allowing their cancer drugs to be used as part of next phase trials. 3: Multiple due dilligence on deals to take on near production or production drugs ongoing. 4: Many activities across all Poolbeg departments to get deals done ongoing at present. So yes I like you an frustrated but Dave Almond mentioned the 3 Ts. To get the right deal takes, time, time, time. They also mentioned considerable interest in the oral-glp and in fact they said they had a call with a potential partner this week. But yes we are still waiting !!!

Well said Flashgarden. 100% agree with you.

Hello Flashgarden. Wonder where is Swizz. He may have a better idea about what might be afoot !!

Hello Cash. I get the inpression that Poolbeg are likely looking for orphan drug status for Polb-001 in advance of any partnering deal. It would improve Poolbegs barganing position. Anyway hope all well with you !

Hi there Moniman. Good advice !!

Of course there will be no fund raise before share price rises 200/300 % and perhaps prior to Nasdaq listing. 12m sterling is in the bank and prudently managed. Polb-001 is becoming more valuable every day. I get the sneaky suspicion that Polbeg are looking for orphan status for Polb-001. If granted it would make it even more valuable. Obviously before concluding a deal you want all details relating to Polb-001 denomination resolved plus extensive IP patenting in place. So whilst the shorters play their games the wise investor should hold and be patient. We will be rewarded very nicely !!!

Sell your Shares Stt1 if you believe your own comments. That would be the wise course of action. I believe the opposite so I will hold and add,. You keep mentioning revenues. And you are correct. Presently no revenues. But we all know a major inflection point is coming with Polb-001. I Expect a good upfront payment and a generous deal. If you believe otherwise then the wise course of action would be to sell your shares. So I can explain why I hold shares based on my expectations. Can you Stt1 ?

A very interesting Webinar. At least 2 of the top10 Major Pharma companies expressing serious interest

In Polb-001. There will be a dual Nasdaq listing within one year. Share price will double to treble before the Nasdaq listing. Partnering Deals are being worked on. A placing will only happen once share price is 2/3 times higher and for the purposes if growing the company in order to benefit further existing shareholders. Poolbeg actively looking at conpanies and products to buy. In fact they had discussions with an American compsny this morning. Will not repeat the mistake of Amryt whe Share Price should have risen further but followibg the merger with Chiasma the Chiasna managment sold a millions of options and depressed Amryt share price. Poolbeg will eventually be bought out with a 2bn valuation a credible target. Silk Road orphan drug a great opportunity and further deals and drugs being targetted. So very very positive.

Interesting regarding Silk Road Therapeutics

“”””"””””

Clinical stage company focused on rare diseases and 505b2 regulatory pathway. Our lead product SRT-001 ($200M annual revenue potential determined by independent third party) for Behcet's Disease showed very promising results at the Phase 2 proof-of-concept trial. The results of the trial were presented at American College of Rheumatologyannual meeting on November 2019. On January 2020, our second product SRT-002 received a "May Proceed" letter from FDA for starting a Phase 2 proof-of-concept trial in the US.

“””””"